Survival and toxicity following chemoradiation for carcinoma of the cervix - impact of multiple-phase treatment and shielding.
AffiliationHall Edwards Radiotherapy Research group, Cancer Centre, Queen Elizabeth Hospital, Birmingham, U.K.
MetadataShow full item record
AbstractWe report on outcomes and significant grade 3-4 late toxicities between January 1999 and October 2006 following introduction of multi-phase treatment and effect of shielding in treatment of cervical cancer with concurrent chemoradiation.
CitationSurvival and toxicity following chemoradiation for carcinoma of the cervix - impact of multiple-phase treatment and shielding. 2015, 35 (10):5567-74 Anticancer Res
- A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
- Authors: Wang JQ, Wang T, Shi F, Yang YY, Su J, Chai YL, Liu Z
- Issue date: 2015
- Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
- Authors: Lim A, Sia S
- Issue date: 2012 Mar 15
- Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
- Authors: Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, Lee SP, Hong JH
- Issue date: 2012 Oct 1
- Is there a role for adjuvant hysterectomy after suboptimal concurrent chemoradiation in cervical carcinoma?
- Authors: Walji N, Chue AL, Yap C, Rogers LJ, El-Modir A, Chan KK, Singh K, Fernando IN
- Issue date: 2010 Mar
- Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study.
- Authors: Lee TS, Kang SB, Kim YT, Park BJ, Kim YM, Lee JM, Kim SM, Kim YT, Kim JH, Kim KT
- Issue date: 2013 Jun 1